Skip to main content
Erschienen in: Neurological Sciences 8/2020

26.06.2020 | COVID-19 | COVID-19 Zur Zeit gratis

Management of COVID-19 in people with epilepsy: drug considerations

verfasst von: Ali A. Asadi-Pooya, Armin Attar, Mohsen Moghadami, Iman Karimzadeh

Erschienen in: Neurological Sciences | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

People with epilepsy (PWE) are neither more likely to be infected by the coronavirus nor are they more likely to have severe COVID-19 manifestations because they suffer from epilepsy. However, management of COVID-19 in PWE may be more complicated than that in other individuals. Drug-drug interactions could pose significant challenges and cardiac, hepatic, or renal problems, which may happen in patients with severe COVID-19, may require adjustment to antiepileptic drugs (AEDs). In this review, we first summarize the potential drug-drug interactions between AEDs and drugs currently used in the management of COVID-19. We then summarize other challenging issues that may happen in PWE, who have COVID-19 and are receiving treatment.
Literatur
1.
Zurück zum Zitat Rothan HA, Byrareddy SN (2020) The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 109:102433CrossRef Rothan HA, Byrareddy SN (2020) The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 109:102433CrossRef
2.
Zurück zum Zitat Asadi-Pooya AA, Simani L (2020) Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci 413:116832CrossRef Asadi-Pooya AA, Simani L (2020) Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci 413:116832CrossRef
4.
Zurück zum Zitat Patsalos PN (2013) Drug interactions with the newer antiepileptic drugs (AEDs)—part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet 52:927–966CrossRef Patsalos PN (2013) Drug interactions with the newer antiepileptic drugs (AEDs)—part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet 52:927–966CrossRef
5.
Zurück zum Zitat Perucca E (2005) Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61:246–255CrossRef Perucca E (2005) Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61:246–255CrossRef
6.
Zurück zum Zitat Asadi-Pooya AA, Sperling MR (2016) Antiepileptic drugs: a clinician’s manual, Second edn. Oxford University Press, New York Asadi-Pooya AA, Sperling MR (2016) Antiepileptic drugs: a clinician’s manual, Second edn. Oxford University Press, New York
10.
Zurück zum Zitat Nguyen T, McNicholl I, Custodio JM, Szwarcberg J, Piontkowsky D (2016) Drug interactions with cobicistat- or ritonavir-boosted Elvitegravir. AIDS Rev 18:101–111PubMed Nguyen T, McNicholl I, Custodio JM, Szwarcberg J, Piontkowsky D (2016) Drug interactions with cobicistat- or ritonavir-boosted Elvitegravir. AIDS Rev 18:101–111PubMed
14.
Zurück zum Zitat Huang CW, Brown S, Pillay N et al (2018) Electroencephalographic and electrocardiographic effect of intravenous lacosamide in refractory focal epilepsy. J Clin Neurophysiol 35:365–369CrossRef Huang CW, Brown S, Pillay N et al (2018) Electroencephalographic and electrocardiographic effect of intravenous lacosamide in refractory focal epilepsy. J Clin Neurophysiol 35:365–369CrossRef
17.
Zurück zum Zitat van der Lee MJ, Dawood L, ter Hofstede HJ, de Graaff-Teulen MJ, van Ewijk-Beneken Kolmer E, Caliskan-Yassen N, Koopmans PP, Burger DM (2006) Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 80:159–168CrossRef van der Lee MJ, Dawood L, ter Hofstede HJ, de Graaff-Teulen MJ, van Ewijk-Beneken Kolmer E, Caliskan-Yassen N, Koopmans PP, Burger DM (2006) Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 80:159–168CrossRef
18.
Zurück zum Zitat Dhatt MS, Gomes JA, Reddy CP, Akhtar M, Caracta AR, Lau SH, Damato AN (1979) Effects of phenytoin on refractoriness and conduction in the human heart. J Cardiovasc Pharmacol 1:3–18CrossRef Dhatt MS, Gomes JA, Reddy CP, Akhtar M, Caracta AR, Lau SH, Damato AN (1979) Effects of phenytoin on refractoriness and conduction in the human heart. J Cardiovasc Pharmacol 1:3–18CrossRef
19.
Zurück zum Zitat Kenneback G, Bergfeldt L, Vallin H, Tomson T, Edhag O (1991) Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. Am Heart J 121:1421–1429CrossRef Kenneback G, Bergfeldt L, Vallin H, Tomson T, Edhag O (1991) Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. Am Heart J 121:1421–1429CrossRef
23.
Zurück zum Zitat Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W, American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, Council on Cardiovascular Nursing, American College of Cardiology Foundation (2010) Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 55:934–947CrossRef Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W, American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, Council on Cardiovascular Nursing, American College of Cardiology Foundation (2010) Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 55:934–947CrossRef
24.
Zurück zum Zitat Farrokh S, Tahsili-Fahadan P, Ritzl EK, Lewin JJ 3rd, Mirski MA (2018) Antiepileptic drugs in critically ill patients. Crit Care 22:153CrossRef Farrokh S, Tahsili-Fahadan P, Ritzl EK, Lewin JJ 3rd, Mirski MA (2018) Antiepileptic drugs in critically ill patients. Crit Care 22:153CrossRef
25.
Zurück zum Zitat Brigo F, Lattanzi S, Nardone R, Trinka E (2019) Intravenous brivaracetam in the treatment of status epilepticus: a systematic review. CNS Drugs 33:771–781CrossRef Brigo F, Lattanzi S, Nardone R, Trinka E (2019) Intravenous brivaracetam in the treatment of status epilepticus: a systematic review. CNS Drugs 33:771–781CrossRef
26.
Zurück zum Zitat Trinka E, Kälviäinen R (2017) 25 years of advances in the definition, classification and treatment of status epilepticus. Seizure 44:65–73CrossRef Trinka E, Kälviäinen R (2017) 25 years of advances in the definition, classification and treatment of status epilepticus. Seizure 44:65–73CrossRef
28.
30.
Zurück zum Zitat Iroegbu JD, Ifenatuoha CW, Ijomone OM (2020) Potential neurological impact of coronaviruses: implications for the novel SARS-CoV-2. Neurol Sci 41:1329–1337 Iroegbu JD, Ifenatuoha CW, Ijomone OM (2020) Potential neurological impact of coronaviruses: implications for the novel SARS-CoV-2. Neurol Sci 41:1329–1337
32.
Zurück zum Zitat Asadi-Pooya AA (2020) Seizures associated with coronavirus infections. Seizure 79:49–52CrossRef Asadi-Pooya AA (2020) Seizures associated with coronavirus infections. Seizure 79:49–52CrossRef
35.
Zurück zum Zitat Mehra MR, Desai SS, Ruschitzka F, Patel AN (2020) Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet S0140-6736(20):31180–31186 Mehra MR, Desai SS, Ruschitzka F, Patel AN (2020) Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet S0140-6736(20):31180–31186
Metadaten
Titel
Management of COVID-19 in people with epilepsy: drug considerations
verfasst von
Ali A. Asadi-Pooya
Armin Attar
Mohsen Moghadami
Iman Karimzadeh
Publikationsdatum
26.06.2020
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 8/2020
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-020-04549-5

Weitere Artikel der Ausgabe 8/2020

Neurological Sciences 8/2020 Zur Ausgabe

Neu in den Fachgebieten Neurologie und Psychiatrie